Tag: drug-eluting stents
SWEDEPAD unplanned interim analysis shows no difference in all-cause mortality for...
An unplanned interim analysis of the registry-based SWEDEPAD clinical trial, in which patients with peripheral arterial disease received treatment with paclitaxel-coated (drug-coated balloons or...
MHRA issues medical device alert for paclitaxel use in the UK
Do not use paclitaxel drug-coated balloons (DCBs) or drug-eluting stents (DESs) in the routine treatment of patients with intermittent claudication until further notice, a...
Without additional long-term and patient-level data, Katsanos et al’s conclusion is...
By Thomas Zeller
The Katsanos et al meta-analysis reports an increased risk of mortality beyond one year across randomised studies of paclitaxel-coated balloons (DCB) and...
Deployable coating stents delivers drug more uniformly than traditional durable coated...
CBSET, a not-for-profit preclinical research institute dedicated to translational research, education, and advancement of medical technologies, has announced that its scientists have published data...
Angiolite BTK below-the-knee sirolimus-eluting stent receives CE mark approval
iVascular has announced the release of Angiolite BTK, a sirolimus-eluting stent which has received CE mark approval for treating chronic and acute arterial lesions in...
Cook launches 140mm Zilver PTX drug-eluting stent
Cook has extended its Zilver PTX product portfolio with a 140mm drug-eluting stent. Physicians will now be able to treat longer lesions with just...
Stefan Müller-Hülsbeck: The current drug-eluting stent landscape
In this interview, Stefan Müller-Hülsbeck, Diako Hospital, Flensburg, Germany, explains the implications of fresh two-year drug-eluting stent data from the MAJESTIC trial, and discusses...
Current status on drug-eluting devices in dialysis access
Dialysis access fistulae and grafts are life-saving in patients with renal insufficiency and failure. Numbers of patients requiring haemodialysis have continued to rise over...
